Clinical Trials Browser

BEBT-908 × Clear all

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06164327 2023-12-11

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT06082596 2023-10-13

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT06074107 2023-10-11

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

Phase 2 Unknown

Recurrence, Lymphoma, Large B-Cell, Diffuse